Krista Kinneer

发表

EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner

Zhan Xiao, S. Coats, B. Jallal, 2012, Cancer biology & therapy.

A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.

Damon L. Meyer, D. Jackson, Herren Wu, 2008, Cancer research.

Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™

P. Kiener, M. Kinch, S. Coats, 2006, Molecular Cancer Therapeutics.

Size fractionation of bacterial functional diversity within soils

Krista Kinneer, 2020 .

Induction of murine NAD(P)H:quinone oxidoreductase by 2,3,7,8-tetrachlorodibenzo-p-dioxin requires the CNC (cap 'n' collar) basic leucine zipper transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2): cross-interaction between AhR (aryl hydrocarbon receptor) and Nrf2 signal transduc

Y. Kan, Q. Ma, J. Chan, 2004, The Biochemical journal.

Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.

Herren Wu, R. Christie, Changshou Gao, 2017, Molecular pharmaceutics.

Inhibition of nuclear factor kappaB by phenolic antioxidants: interplay between antioxidant signaling and inflammatory cytokine expression.

Q. Ma, Jianping Ye, Krista Kinneer, 2003, Molecular pharmacology.

Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells

Paul G. Hynes, E. Hurt, Ruoyan Chen, 2018, Leukemia.

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.

P. Kiener, M. Kinch, S. Coats, 2006, Molecular cancer therapeutics.

Chemoprotection by Phenolic Antioxidants

Q. Ma, Krista Kinneer, 2002, The Journal of Biological Chemistry.

BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression

Y. Tai, Yuyin Li, Suizhao Wang, 2021, Clinical Cancer Research.

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

M. Dimopoulos, Shaji K. Kumar, A. Yee, 2020 .

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

N. Munshi, Y. Tai, Yuyin Li, 2020, Leukemia.

SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads

M. Rebelatto, S. Sridhar, K. Papadopoulos, 2018, Clinical Cancer Research.

Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma

E. Hurt, Ruoyan Chen, Y. Tai, 2017 .

Chemoprotection by Phenolic Antioxidants INHIBITION OF TUMOR NECROSIS FACTOR INDUCTION IN MACROPHAGES*

Q. Ma, Krista Kinneer, 2002 .

Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.

Herren Wu, Herren Wu, Changshou Gao, 2018, Bioorganic & medicinal chemistry letters.

First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.

Toshio Shimizu, F. Meric-Bernstam, M. Rebelatto, 2022, Journal of Clinical Oncology.

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response

R. Hollingsworth, Zhan Xiao, R. Tammali, 2016, Molecular Cancer Therapeutics.

Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.

M. Albertella, Z. Cooper, R. Christie, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.